doi: 10.1093/cid/civ484.
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience
Affiliations
- PMID: 26224766
- DOI: 10.1093/cid/civ484
Item in Clipboard
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience
Clin Infect Dis.
.
Abstract
The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.
Keywords: EMA; PK/PD; in vitro models; qualification; tuberculosis.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425. Clin Infect Dis. 2015. PMID: 26224767
-
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S5-9. doi: 10.1093/cid/civ424. Clin Infect Dis. 2015. PMID: 26224771
-
Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.Methods Mol Biol. 2021;2314:715-731. doi: 10.1007/978-1-0716-1460-0_31. Methods Mol Biol. 2021. PMID: 34235677
-
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.J Infect Dis. 2015 Jun 15;211 Suppl 3:S96-S106. doi: 10.1093/infdis/jiu610. J Infect Dis. 2015. PMID: 26009618 Review.
-
Preclinical Efficacy Testing of New Drug Candidates.Microbiol Spectr. 2017 Jun;5(3):10.1128/microbiolspec.tbtb2-0034-2017. doi: 10.1128/microbiolspec.TBTB2-0034-2017. Microbiol Spectr. 2017. PMID: 28643624 Free PMC article. Review.
Cited by
-
Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.Antimicrob Agents Chemother. 2023 May 1;65(5):e02213-20. doi: 10.1128/AAC.02213-20. Epub 2021 Mar 8. Antimicrob Agents Chemother. 2023. PMID: 33685903 Free PMC article.
-
Research in the Field of Drug Design and Development.Pharmaceuticals (Basel). 2023 Sep 11;16(9):1283. doi: 10.3390/ph16091283. Pharmaceuticals (Basel). 2023. PMID: 37765091 Free PMC article. Review.
-
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modeling.J Pharmacokinet Pharmacodyn. 2025 Jul 23;52(4):40. doi: 10.1007/s10928-025-09986-3. J Pharmacokinet Pharmacodyn. 2025. PMID: 40699396
-
Salmonella antimicrobials inherited and the non-inherited resistance: mechanisms and alternative therapeutic strategies.Front Microbiol. 2023 May 25;14:1176317. doi: 10.3389/fmicb.2023.1176317. eCollection 2023. Front Microbiol. 2023. PMID: 37303797 Free PMC article. Review.
-
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6. Antimicrob Agents Chemother. 2023. PMID: 36877034 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
